登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次现金管理受托方：中国工商银行股份有限公司厦门海沧支行（以下 简称"工商银行"）。 币结构性存款产品专户型2024年第310期Q款,365天。 ● 履行的审议程序：北京万泰生物药业股份有限公司（以下简称"公司"） 于2024年1月15日召开第五届董事会第二十五次会议、第五届监事会第二十五次会议，审议通过了《关 于使用部分闲置募集资金进行现金管理的议案》，同意公司使用最高额度不超过人民币20亿元（含）的 暂时闲置非公开发行股票募集资金适时投资安全性高、流动性好的保本型产品，单项产品期限最长不超 过12个月。该额度自公司董事会审议通过之日起12个月内有效，可由公司及全资子公司共同循环滚动使 用。具体内容详见公司于指定信息披露媒体披露的《北京万泰生物药业股份有限公司关于使用部分闲置 募集资金进行现金管理的公告》（公告编号：2024-005）。 公司于2025年1月14日召开第六届董事会第六次会议、第六届监事会第六次 ...

Trading Information Summary - On July 31, 2025, Wante Bio (603392) closed at 58.54 CNY, down 0.31%, with a turnover rate of 0.4% and a trading volume of 50,300 shares, amounting to a total transaction value of 296 million CNY [1] - On the same day, the fund flow for Wante Bio showed a net outflow of 538,100 CNY from institutional investors, accounting for 0.18% of the total transaction value, while retail investors had a net outflow of 1,267,360 CNY, representing 4.28% of the total transaction value [1][3] Company Announcement Summary - Wante Bio announced the redemption of 700 million CNY from a structured deposit product linked to the exchange rate, which was purchased from the Industrial and Commercial Bank of China [1] - The company held meetings on January 15, 2024, and January 14, 2025, to approve the use of idle fundraising for cash management, allowing for investments in safe and liquid principal-protected products, with a maximum investment limit of 2 billion CNY and 1.5 billion CNY for different fundraising sources [1] - As of the announcement date, Wante Bio had invested a total of 2,129.15 million CNY in financial management over the past twelve months, recovering 1,550 million CNY in principal and earning 38.19 million CNY in returns, with an outstanding principal amount of 579.15 million CNY [1]

Investment Overview - On October 12, 2023, the company approved the establishment of a joint venture with Evonik (China) Investment Co., Ltd. to form "Evonik Blue Biological Technology (Shandong) Co., Ltd." in Huimin County, Shandong Province [2] - The registered capital of the joint venture is RMB 37.5 million, with the company contributing RMB 16.875 million (45%) and Evonik contributing RMB 20.625 million (55%) [2] Termination of Investment - The joint venture and its Qingdao branch will be dissolved and liquidated as per the reconciliation agreement signed on July 31, 2025, due to operational considerations and future business planning [4][5] - The board of directors approved the termination of the investment with a unanimous vote of 5 in favor [5] Reconciliation Agreement Details - The agreement includes the dissolution and liquidation of the joint venture and its Qingdao branch, with both parties agreeing to return relevant patents, technologies, trademarks, and strains to the company [6][8] - A new processing agreement will be signed for continued cooperation in the GHS product field, allowing both parties to independently conduct related business under applicable antitrust laws starting August 1, 2025 [9] Impact on the Company - The dissolution and liquidation of the joint venture are not expected to have a significant adverse impact on the company's operations or financial status [12] - The new agreement framework is anticipated to maintain cooperation in the GHS product area without major disruptions to existing business activities [12]

证券时报·数据宝统计显示，特宝生物今日收盘价为91.33元，上涨7.46%，日换手率为2.97%，成交额为 11.04亿元，全天主力资金净流出1.93亿元，近5日该股累计上涨19.82%，近5日资金合计净流出1.42亿 元。 两融数据显示，该股最新融资余额为14.14亿元，近5日增加3404.87万元，增幅为2.47%。（数据宝） 7月31日特宝生物大宗交易一览 特宝生物7月31日大宗交易平台出现一笔成交，成交量10.95万股，成交金额1000.00万元，大宗交易成交 价为91.33元。该笔交易的买方营业部为国泰海通证券股份有限公司总部，卖方营业部为广发证券股份 有限公司厦门环岛东路证券营业部。 进一步统计，近3个月内该股累计发生18笔大宗交易，合计成交金额为3.50亿元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | | | | | | | | 国泰海通证券股份 | 广发证券股份有限公司厦门 | | 10.95 | 1000 ...

Group 1 - The Shanghai Stock Exchange will hold its 29th listing review committee meeting on August 7, 2025, to review the initial public offering (IPO) of Suzhou Fengbei Biotechnology Co., Ltd. [1] - Fengbei Biotechnology plans to issue no more than 35.90 million shares, with the public offering accounting for at least 25% of the total share capital after the issuance [1] - The company aims to raise 750 million yuan, which will be used for the construction of projects including an annual production of 300,000 tons of oleic acid methyl ester, 10,000 tons of industrial-grade mixed oil, 50,000 tons of agricultural microbial agents, 10,000 tons of compound microbial fertilizers, and by-products such as 50,000 tons of biodiesel and 8,200 tons of glycerol [1] Group 2 - The lead underwriter for this issuance is Guotai Junan Securities Co., Ltd., with representatives Hu Bo and Jin Xiang overseeing the process [1]

Group 1: Clinical Trials and Biotechnology - The phase I clinical trial for the type II herpes simplex virus mRNA vaccine developed by Zhuhai Lifanda Biotechnology Co., Ltd. and Changchun Baike Biotechnology Co., Ltd. has commenced, focusing on safety, tolerability, and immunogenicity among participants aged 18 to 55 [1] - Zhuhai Lifanda, established in June 2019, specializes in the development of mRNA drugs targeting infectious diseases, tumors, rare diseases, and other protein deficiency-related conditions [1] Group 2: Financial Services and Cross-Border Investment - The first EF account under the Macao dollar ODI business has been successfully processed by the Hengqin branch of China Construction Bank for Chip Tide (Zhuhai) Technology Co., Ltd., marking a significant milestone in cross-border financial services [2] - As of June 2025, the Hengqin branch has opened 103 EF accounts, becoming the first pilot bank to surpass 100 accounts, with a total fund transfer and foreign exchange volume exceeding 700 million yuan [2] Group 3: Real Estate and Housing Solutions - The "He Yu" rental platform, launched by Hengqin Shenhe Asset Management Co., Ltd., aims to address housing challenges for talent in the Hengqin Guangdong-Macao Deep Cooperation Zone by increasing the supply of high-quality housing [3] - The platform intends to enhance the rental process through technology, ensuring efficient matching between talent and housing resources, and aims to create a community ecosystem for residents [3] Group 4: Pharmaceutical and Traditional Medicine - Guangdong-Macao Pharmaceutical Co., Ltd., the only Chinese and EU GMP certified traditional Chinese medicine manufacturer in the Hengqin Guangdong-Macao Deep Cooperation Zone, has established a comprehensive production and quality management system [4] - As of July 2025, the company has provided production and registration agency services for over 20 types of Macao traditional Chinese medicine products, facilitating the integration of Macao's international platform with Hengqin's production capabilities [4] Group 5: Tourism and Cross-Border Travel - The Hengqin port has seen over 2.08 million inbound and outbound travelers during the summer period, representing a 27.6% increase compared to the same period last year, with 1.28 million from the mainland [5] - The implementation of convenient travel policies, such as "one visa multiple entries," has significantly boosted cross-border tourism products between Hengqin and Macao [6] Group 6: Industry Events and Support Initiatives - The 20th "China Chip" excellent product solicitation event is set to take place on October 29 in the Hengqin Guangdong-Macao Deep Cooperation Zone, with submissions open until August 30 [7] - The event aims to recognize outstanding chip products and enterprises, particularly in the automotive industry and RISC-V ecosystem promotion [7] - The cross-border e-commerce industry support application for the first half of 2025 has been officially launched, encouraging service providers to support e-commerce enterprises with various professional services [8]

华恒生物表示，此举有利于深入推进公司全球化发展战略，提升品牌影响力与核心竞争力，巩固行业领 先地位。并充分借助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，全面提升公 司治理水平和综合实力。 （文章来源：证券日报） 本报讯 （记者徐一鸣）7月30日，安徽华恒生物科技股份有限公司（以下简称"华恒生物"）发布公告 称，公司正在筹划发行境外股份（H股）并在香港联合交易所有限公司上市事宜。 ...

Core Viewpoint - Lidman (300289.SZ) announced a significant asset restructuring plan, intending to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, which has led to a stock price surge of 19.93% to 7.04 yuan [1][2]. Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as per the regulations, and it will not involve issuing new shares or result in a change of control [2][3]. - The funding for the acquisition will come from the company's own funds and bank merger loans [2][3]. - The framework agreement for the acquisition was signed on July 30, 2025, and the company did not hold any shares in the target company prior to this transaction [1][2]. Group 2: Financial Performance - In 2024, the company reported a revenue of 370.23 million yuan, a decrease of 19.79% compared to 2023 [3][4]. - The net profit attributable to shareholders was -75.10 million yuan, a decline of 589.66% from the previous year [3][4]. - The net cash flow from operating activities was 62.41 million yuan, down 52.29% year-on-year [3][4]. Group 3: Recent Quarterly Performance - For Q1 2025, the company reported a revenue of 78.91 million yuan, a decrease of 16.61% year-on-year [4]. - The net profit attributable to shareholders was -1.25 million yuan, an improvement of 53.73% compared to the same period last year [4]. - The net cash flow from operating activities for Q1 2025 was 10.69 million yuan, an increase of 25.64% year-on-year [4].

中国经济网北京7月31日讯华恒生物（688639.SH）昨晚发布关于筹划公司在香港联合交易所有限公司 上市的提示性公告。 华恒生物为深入推进公司全球化发展战略，提升品牌影响力与核心竞争力，巩固行业领先地位，充分借 助国际资本市场的资源与机制优势，优化资本结构，拓宽多元融资渠道，全面提升公司治理水平和综合 实力，正在筹划发行境外股份（H股）并在香港联合交易所有限公司（以下简称"香港联交所"）上市事 宜（以下简称"本次H股上市"）。公司正与相关中介机构就本次H股上市的具体推进工作进行商讨，相 关细节尚未确定，本次H股上市不会导致公司控股股东和实际控制人发生变化。 华恒生物于2021年4月22日在上交所科创板上市，保荐机构为兴业证券股份有限公司，保荐代表人为黄 超、饶毅杰。华恒生物公开发行募集资金总额为62532.00万元，募集资金净额为55925.88万元。华恒生 物于2021年4月16日披露的招股书显示，公司募集资金5.71亿元，分别用于交替年产2.5万吨丙氨酸、缬 氨酸项目、发酵法丙氨酸5000吨/年技改扩产项目、补充流动资金。 根据中国证券监督管理委员会出具的《关于同意安徽华恒生物科技股份有限公司向特定对象 ...

中国经济网北京7月31日讯 市场早盘震荡分化，截至午间收盘，上证指数报3591.26点，跌幅 0.68%；深证成指报11152.77点，跌幅0.45%；创业板指报2377.84点，涨幅0.43%。 | 序号 | 板块 | 涨跌幅(%)▼ | 总成交量(万手) ▼ | 总成交额(亿元) ▼ | 净流入(亿元) ▼ | 上涨家数 | 下跌家数 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 化学制药 | 2.21 | 3736.11 | 563.27 | 21.08 | 112 | 39 | | 2 | 软件开发 | 2.15 | 2165.17 | 483.02 | 48.85 | 109 | 28 | | 3 | 生物制品 | 2.14 | 666.38 | 151.85 | 9.26 | 38 | 14 | | 4 | 通信设备 | 1.85 | 1503.36 | 581.04 | 35.32 | 67 | 18 | | 5 | 医疗服务 | 1.71 | 908.17 | 236.63 | 5.05 | 41 | 12 | | б | ...